FlagInternationalUnited States
 

Overview

Corporate Profile

Uroplasty, Inc. is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices.

Uroplasty products are typically used when a patient’s treatment goals are not met after conservative and/or drug therapies. Providers and patients alike appreciate that Uroplasty products provide low-risk, effective alternatives to invasive surgery. And because these treatments can be delivered in an office or outpatient setting, the end result is that more patients are given the opportunity to transform their lives with successful treatment.

 
Stock Quote
UPI (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$2.42
Change (%) Stock is Up 0.01 (0.41%)
Volume48,027
Data as of 11/21/14 3:49 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle  
11/13/14Uroplasty To Participate In The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum
MINNEAPOLIS, Nov. 13, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the Canaccord Genuity 2014 Medical Technology & Diagnostics Forum on Thursday, November 20.  Rob Kill, President and CEO, will present at 4:00pm ET and meet with investors one on one at the conference at the Westin Grand Central in New... 
 Printer Friendly Version
10/23/14Uroplasty Reports Record Fiscal Second Quarter Revenue
~ Global Urgent PC Sales Up 17.5% ~~ Fiscal 2015 Guidance Reaffirmed MINNEAPOLIS, Oct. 23, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fiscal 2015 second quarter ended September 30, 2014.  Global revenue for the Company's Urgent® PC Neuromodulation System grew 17.5% to $4.3 million, a new quarterly revenue reco... 
 Printer Friendly Version
10/15/14Healthcare Industry Leader Kenneth H. Paulus Joins Uroplasty's Board of Directors
Brings 30 Years of Healthcare Delivery System Leadership Experience to Uroplasty MINNEAPOLIS, Oct. 15, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today that Kenneth H. Paulus has been appointed to the Company's Board of Directors effective October 15, 2014. Mr. Paulus will chair the Board's compensation committee and serve on the nomi... 
 Printer Friendly Version
10/09/14Uroplasty to Announce Second Quarter Fiscal Year 2015 Financial Results on October 23, 2014
MINNEAPOLIS, Oct. 9, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, will release financial results for the second quarter ended September 30, 2014 after the market close on Thursday, October 23, 2014. The Company will host a conference call and webcast to discuss these results on Thursday, October 23, 2014 at 4:30 p.m. Eastern Time (3:30 p.m. Centra... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Uroplasty, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.